Full-Time

Senior Scientist

Assay Development, Chemistry

Glyphic Biotechnologies

Glyphic Biotechnologies

11-50 employees

Next-generation protein sequencing platform provider

Compensation Overview

$123k - $187.6k/yr

Berkeley, CA, USA

In Person

Master's, PhD

Category
Biology & Biotech (1)
Required Skills
Chemical Biology
Biochemistry

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Requirements
  • Advanced degree in organic chemistry, chemical biology, biochemistry, or a related field
  • MS/PhD with 6+/4+ years of experience (for Senior Scientist)
  • MS/PhD with 8+/6+ years of experience (for Staff Scientist)
  • Demonstrated experience developing site-selective bioconjugation chemistry for native peptides — including N-terminal, C-terminal, and side-chain modification strategies — using click chemistry (CuAAC, SPAAC, IEDDA), NHS-ester coupling, and related bioorthogonal approaches in multi-component peptide systems.
  • Experience developing multi-step workflows using peptides, oligonucleotides and bioconjugation techniques including in solution and on surfaces.
  • Proficiency with analytical characterization of complex conjugates and assay intermediates: HPLC (RP and IEX), LC-MS/MS, UV-Vis; demonstrated ability to develop and validate analytical methods for novel chemical entities.
  • Method-development mindset: history of building and adapting new chemical approaches rather than executing established protocols.
  • Ability to function as both an independent contributor and a collaborative partner in a cross-functional team environment.
  • Excellent problem-solving skills and attention to detail.
  • Excellent written and verbal communication skills, with the ability to work seamlessly with colleagues from diverse scientific and technical backgrounds.
  • Ability to thrive in a fast-paced environment with evolving priorities.
Responsibilities
  • Expansion assay chemistry & sample loading: Optimize bioconjugation methods for peptide loading into the expansion assay; establish robust, high-efficiency loading protocols that perform reliably across diverse peptide populations and physicochemical characteristics.
  • Identify, characterize, and optimize peptide labeling during the ProSE sequencing assay, leveraging mechanistic understanding of Edman chemistry and amino acid side-chain reactivity and stability.
  • Develop reagents and methods to maximize the stability of peptides, DNA, and peptide-DNA chimeras throughout the ProSE sequencing assay.
  • Partner with the Chemistry team to develop amino acid side-chain protection chemistries.
  • Evaluate compatibility of new chemistries with existing assay components, reagents, and multi-cycle sequencing conditions.
  • Evaluate emerging chemistries from the literature and internal pipeline; synthesize and test candidate reagents.
Desired Qualifications
  • Familiarity with nanopore or single-molecule sequencing chemistry, and the demands it places on assay reagent purity, stability, and uniformity.
  • Experience with solid-phase peptide synthesis (SPPS), including on-resin modification, selective sidechain deprotection, and non-standard protecting group strategies.
  • Familiarity with statistical and DOE-based experimental design for chemistry optimization.
  • Prior experience in an early-stage biotech or tools/diagnostics company.
  • Navigates complex team dynamics, partnerships, and challenges with creativity and logic.
  • Operates with adaptability, urgency, and flexibility in evolving environments, thriving in ambiguity.
  • Drives work forward without needing to be asked, taking responsibility for outcomes rather than tasks.
  • Treats obstacles as problems to be creatively solved, not reasons something can’t be done.
  • Applies sound judgment to the best available information, testing, learning, and iterating.
  • Shares early and directly when assumptions change, results are unclear, or timelines are at risk.
Glyphic Biotechnologies

Glyphic Biotechnologies

View

Glyphic Biotechnologies is advancing proteomics by building a next-generation protein sequencing platform. The core product is designed to reveal detailed information about proteins, helping researchers and medical institutions gain new insights into biology and disease. The platform supports sequencing services for researchers and may be licensed to other organizations, generating revenue from service fees and licensing agreements. Unlike many competitors that focus on smaller-scale tools, Glyphic emphasizes a first-of-its-kind sequencing capability for proteins, along with diverse deployment options (serving research labs directly and via licensing). The company's goal is to enable deeper understanding of bodily functions through protein data and to bring its sequencing technology to broader use in the life sciences through services and licensing deals.

Company Size

11-50

Company Stage

Early VC

Total Funding

$43M

Headquarters

New York City, New York

Founded

2021

Get referred to Glyphic Biotechnologies

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Glyphic raised $38 million by September 2025, extending runway for platform development.
  • Glyphic posted multiple 2026 hires in Berkeley, signaling active buildout and execution.
  • NIH and Bakar Labs visibility plus 2025 patent publications validate technical momentum.

What critics are saying

  • Glyphic still sells no commercial platform, so revenue depends on unproven hardware delivery in 2026.
  • Protein sequencing must beat mass spectrometry, or customers ignore Glyphic’s expensive workflow.
  • If ProSE misses accuracy or throughput targets, the 2025 Series A becomes a financing trap.

What makes Glyphic Biotechnologies unique

  • Glyphic’s ProSE sequences proteins de novo, one molecule at a time, without databases.
  • Glyphic claims single-molecule discrimination of all 20 amino acids and PTMs in Berkeley, 2026.
  • Glyphic holds issued patents and a 2025 nanopore peptide-sequencing filing around core chemistry.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Company Match

Unlimited Paid Time Off

Commuter Benefits

Paid Maternity and Paternity Leave

Home Office Stipend

Wellness Program

Company Equity

Employee Stock Purchase Plan

Growth & Insights and Company News

Headcount

6 month growth

6%

1 year growth

0%

2 year growth

3%
Labs of Latvia
Dec 3rd, 2024
Latvian LongeVC invests in US startup Glyphic Biotechnologies

Founded in New York in 2021 by Daniel Estandian and Joshua Yang, Glyphic Biotechnologies is developing a protein sequencing platform that uses single-molecule technology to analyze the sequence of each protein in a complex protein mixture.

BioPharmaTrend
Nov 25th, 2024
LongeVC Invests in Glyphic Biotechnologies

LongeVC has invested in Glyphic Biotechnologies, which is developing single-molecule protein sequencing technology. This innovation surpasses mass spectrometry by enabling precise sequencing of individual proteins in complex mixtures, enhancing protein analysis and broadening applications in drug discovery and diagnostics. The proteomics market, valued at over $30 billion, is set for growth with such advancements. This aligns with LongeVC's mission to support transformative healthcare technologies.

U.S. Securities and Exchange Commission
Feb 21st, 2024
SEC FORM D

The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.The reader should not assume that the information is accurate and complete.

Johnson & Johnson Innovation
Apr 5th, 2023
Awardees of the BLUE KNIGHT™ Resident QuickFire Challenge Strive Toward Inflection Points | Johnson & Johnson Innovation

By: Rachel Rath, Director, BARDA Alliance, Johnson & Johnson Innovation – JLABS & Ashim Subedee, Director, DRIVe Catalyst Office, BARDA

Bakar Labs
Jan 31st, 2023
Glyphic Biotechnologies Wins $409K SBIR Grant From NIH - Bakar Labs

Congratulations to Glyphic Biotechnologies! NIH recently reported the company had been awarded a $409 SBIR grant for their project "Single-molecule protein sequencing by iterative isolation and identification of N-terminal amino acids." The company is developing and commercializing technology to sequence proteins — instead of DNA. They're hiring!